Literature DB >> 28239069

A First-in-Class Drug, Lomitapide, Tailored to Patients with Homozygous Familial Hypercholesterolemia is Just about Meeting with Good News to Them.

Hiroshi Yoshida1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28239069      PMCID： PMC5392476          DOI： 10.5551/jat.ED069

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN： 1340-3478            Impact factor:   4.928


× No keyword cloud information.
  20 in total

Review 1.  The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association.

Authors:  Samuel S Gidding; Mary Ann Champagne; Sarah D de Ferranti; Joep Defesche; Matthew K Ito; Joshua W Knowles; Brian McCrindle; Frederick Raal; Daniel Rader; Raul D Santos; Maria Lopes-Virella; Gerald F Watts; Anthony S Wierzbicki
Journal:  Circulation       Date:  2015-10-28       Impact factor: 29.690

Review 2.  Lipoprotein (a): Coming of Age at Last.

Authors:  Joseph L Witztum; Henry N Ginsberg
Journal:  J Lipid Res       Date:  2016-02-02       Impact factor: 5.922

3.  Monthly PCSK9 inhibitors: The CHOICE for prolonged duration of effect.

Authors:  Luiz Sérgio F de Carvalho; Hiroshi Yoshida
Journal:  Atherosclerosis       Date:  2016-10-13       Impact factor: 5.162

4.  Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan.

Authors:  Tamio Teramoto; Kiyoko Uno; Izuru Miyoshi; Irfan Khan; Katherine Gorcyca; Robert J Sanchez; Shigeto Yoshida; Kazuhiro Mawatari; Tomoya Masaki; Hidenori Arai; Shizuya Yamashita
Journal:  Atherosclerosis       Date:  2016-07-04       Impact factor: 5.162

5.  Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.

Authors:  Dhruv S Kazi; Andrew E Moran; Pamela G Coxson; Joanne Penko; Daniel A Ollendorf; Steven D Pearson; Jeffrey A Tice; David Guzman; Kirsten Bibbins-Domingo
Journal:  JAMA       Date:  2016-08-16       Impact factor: 56.272

Review 6.  PCSK9: A key factor modulating atherosclerosis.

Authors:  Sha Li; Jian-Jun Li
Journal:  J Atheroscler Thromb       Date:  2014-11-18       Impact factor: 4.928

7.  Guidelines for the management of familial hypercholesterolemia.

Authors:  Mariko Harada-Shiba; Hidenori Arai; Shinichi Oikawa; Takao Ohta; Tomoo Okada; Tomonori Okamura; Atsushi Nohara; Hideaki Bujo; Koutaro Yokote; Akihiko Wakatsuki; Shun Ishibashi; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2012-10-25       Impact factor: 4.928

8.  Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.

Authors:  Marina Cuchel; Emma A Meagher; Hendrik du Toit Theron; Dirk J Blom; A David Marais; Robert A Hegele; Maurizio R Averna; Cesare R Sirtori; Prediman K Shah; Daniel Gaudet; Claudia Stefanutti; Giovanni B Vigna; Anna M E Du Plessis; Kathleen J Propert; William J Sasiela; LeAnne T Bloedon; Daniel J Rader
Journal:  Lancet       Date:  2012-11-02       Impact factor: 79.321

9.  Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia.

Authors:  Mariko Harada-Shiba; Katsunori Ikewaki; Atsushi Nohara; Yoshihiko Otsubo; Koji Yanagi; Masayuki Yoshida; Qing Chang; Pamela Foulds
Journal:  J Atheroscler Thromb       Date:  2017-02-02       Impact factor: 4.928

Review 10.  Mendelian randomization studies in coronary artery disease.

Authors:  Henning Jansen; Nilesh J Samani; Heribert Schunkert
Journal:  Eur Heart J       Date:  2014-06-10       Impact factor: 29.983
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.